Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

BACKGROUND: While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood. We exami...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Kiniwa, Yukiko, Nakamura, Kenta, Mikoshiba, Asuka, Ashida, Atsuko, Akiyama, Yasuyuki, Morimoto, Atsushi, Okuyama, Ryuhei
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7968258/
https://ncbi.nlm.nih.gov/pubmed/33731038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08016-y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares